Company / Return on Equity (ROE)
Vaxcyte, Inc. Return on Equity (ROE) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-28.5%
FY2025
5-year range
-35.2% / -14.0%
FY2021-FY2025
Trend
-103.5%
vs FY2024
Sector context
#91 of 190
Health Care
What the data says
Vaxcyte, Inc. reports negative total equity of -28.5% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-28.5% in FY2025 with a 5-year CAGR of -2.7%.
Improved from -32.4% to -28.5% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -5.1pp
- 5-Year Change
- -2.7pp
- 10-Year Change
- -
Sector benchmark
#91 of 190 in Health CareTop 48% of 190This company -28.5% Sector average -50.3%
▼
+43.3% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 103.5% year-over-year.
- Currently 21.8pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2024.
- Lowest return on equity (roe) in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -28.5% | -103.5% |
| FY2024 | -14.0% | +56.7% |
| FY2023 | -32.4% | -38.4% |
| FY2022 | -23.4% | +33.5% |
| FY2021 | -35.2% | -36.6% |
| FY2020 | -25.8% | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026